Eosvision
熹微生物
Eosvision is the English name used in elsewhere's knowledge base for **熹微（苏州）生物医药科技有限公司** (Xiwi Microorganism / Xiwi Medical), a Suzhou-based ophthalmic and regenerative medicine company developing innovative biomaterials and polymer-based medical devices . The company focuses on artificial cornea implants, implantable contact lenses, artificial corneal endothelium, and artificial dermal products .
In December 2024, Eosvision completed a nearly RMB 100 million Series A funding round led by Dalton Venture (道彤投资), with proceeds earmarked for accelerating R&D and clinical trials across its pipeline . Dalton Venture has described the company as specializing in novel bio-modified materials for ophthalmology and regenerative medicine applications .
AI-generated — may contain errors, please verify.
Coverage
A Decade of Dalton, Igniting a New Chapter of Intelligence | Dalton Venture's 2025 Annual Partners Meeting and 10th Anniversary Forum Concludes Successfully
Together, Toward the Brilliance and Distant Horizons of the Next Decade
Riding the Wind, Breaking Boundaries — Tides Surge in Hong Kong | Dalton Venture 2025 CEO Summit Successfully Concludes
At the intersection of technological revolution and industrial transformation, what should be the starting point for the globalization of the life sciences industry? Where should mainland Chinese healthcare innovators set their first foothold for overseas expansion? Against a backdrop of intensifying international competition and sustained policy tailwinds, is Hong Kong — a city that blends international perspective with institutional advantages — emerging as the bridge for tech ventures to reach the world?
Steadfast Progress, Grounded in Action | Dalton Venture's 2024 Year in Review
Looking back at 2024, "adjustment" and "patience" became the defining keywords for venture capital. Yet on the long-distance track of life sciences and medtech, Dalton Venture kept moving forward with steady, deliberate strides. We navigated market fluctuations, caught glimpses of innovation, and helped companies take root and grow through the cycles — writing a new chapter of innovation-driven development with the power of capital.
Xiwi Microorganism Completes Nearly 100 Million Yuan Series A Funding Round Led by Dalton Venture, Building an Innovative Ophthalmic Biology and Polymer Materials Platform | Dalton Venture News
Recently, **Xiwei (Suzhou) Biomedical Technology Co., Ltd.** (hereinafter referred to as "Xiwei Biotech") **announced the completion of a nearly RMB 100 million Series A funding round, led by Dalton Venture**. The proceeds will be used to accelerate the development of its pipeline of ophthalmic and regenerative medicine innovations — including artificial biomimetic corneas, implantable contact lenses, artificial corneal endothelium sheets, and artificial dermis — as well as clinical trials, international regulatory registration, and marketing expansion.
